Incyte (INCY) Tops Q2 EPS by 6c; Raises Jakafi Sales Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Incyte (INCY) Tops Q2 EPS by 6c; Raises Jakafi Sales Guidance

Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs

August 4, 2015 7:00 AM EDT

$142 million of 2015 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 69 percent growth over the same period last year 2015 guidance for Jakafi net product revenues increased to range of $560 million to $575 million, driven by strong underlying demand Positive results from two pivotal trials of baricitinib in rheumatoid arthritis presented at EULAR Multiple abstracts presented at ASCO and EHA, demonstrating continued progress across broad clinical portfolio

Conference Call and Webcast Scheduled Today at 10:00 a.m. ET

... More